Monday, September 17, 2012

IPO DRTX

Well I am reading on this company and decided to stop investigating. My amateur view of balance sheets is they are running a serious loss without hope of near term profit. They have one drug in the pipeline, state that their failure or success will be determined only by this one drug. A larger company sold the rights to this drug to them, why would Pfizer sell a good drug? Leadership and management seem to have some experience but nothing exciting. Price seems low. On the plus side, if this drug works and gains approval it could do very well. I am not interested in that lottery ticket.

No comments:

Post a Comment